Is the MVP Regimen Less Active than Previously Described? : Results of a phase II study in advanced non-small cell lung cancer

References

• Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics 1994. CA Cancer J Clin 1994; 44: 7–26
   PubMed Web of Science ®Google Scholar
• Silverberg E., Lubera J. A. Cancer statistics 1988. CA 1988; 38: 5–22
   Google Scholar
• Haskell C. M. Chemotherapy and survival of patients with non-small cell lung cancer: a contrary view. Chest 1991; 99: 1325–6
   PubMedGoogle Scholar
• Vokes E. E., Bitran J. D., Vogelzang N. J. Chemotherapy for non-small cell lung cancer: the continuing challenge. Chest 1991; 99: 1326–8
   PubMedGoogle Scholar
• Buccheri G. F. Chemotherapy and survival in non-small cell lung cancer: three years later. Chest 1994; 106: 990–2
   PubMedGoogle Scholar
• Sorensen J. B. The role of chemotherapy in non-small cell lung cancer. Radiol Oncol 1994; 28: 386–94
   Google Scholar
• Souquet P. J., Chauvin F., Boissel J. P., et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–09
   PubMed Web of Science ®Google Scholar
• Mulshine J. L., Glatstein E., Ruckdeschel J. C. Treatment of non-small cell lung cancer. J Clin Oncol 1986; 4: 1704–15
   PubMed Web of Science ®Google Scholar
• Ruckdeschel J. C., Metha C. R., Salazar O. M., Creech R. H., Sponzo R. W. Chemotherapy for metastatic non-small cell bronchogenic carcinoma. EST 2575 generation III. HAM verus CAMP. Cancer Treat Rep 1981; 65: 959–63
   PubMedGoogle Scholar
• Ruckdeschel J. C., Finkelstein D. M., Ettinger D. S., Mason B. A., Crech R. H. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575 Generation V-A randomized comparison of four cisplatin containing regimens. J Clin Oncol 1985; 3: 72–9
   PubMed Web of Science ®Google Scholar
• Ruckdeschel J. C., Finkelstein D. M., Ettinger D. S., et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986; 4: 14–22
   PubMed Web of Science ®Google Scholar
• Chahinian A. P., Arnold D. J., Cohen J. M., et al. Chemotherapy for bronchogenic carcinoma: methotrexate, doxorubicin, cyclophosphamide, and lomustine. JAMA 1977; 237: 2392–6
   PubMed Web of Science ®Google Scholar
• World Health Organization. Histologic typing of lung tumors. Am J Clin Pathol 1982; 77: 123–36
   PubMed Web of Science ®Google Scholar
• International Union Against Cancer. TNM classification of malignant tumours. 4th ed. International Union Against Cancer, Geneva 1987; 69–73
   Google Scholar
• Karnofsky D. A., Burchenal J. H. The clinical evaluation of chemotherapeutic agents in cancer. Columbia University Press, New York 1949; 199–205
   Google Scholar
• Mason B. A., Catalano R. B. Mitomycin, vinblastine and cisplatin combination chemotherapy in non-small cell lung cancer (Abstract). Proc Am Soc Clin Oncol 1980; 21: 477
   Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Longo L. D., Duffley P. L., DeVita V. T., Wesley M. N., Hubbard S. M., Young R. C. The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol 1991; 9: 2042–51
   PubMed Web of Science ®Google Scholar
• Dixon W. J. BMDP: Statistical Software. University of California Press, Berkeley 1988; 576–83
   Google Scholar
• Kaplan E. L., Meier F. Non-parametric estimation for incomplete observations. J Am Sta Assoc 1958; 58: 457–581
   Google Scholar
• Miller V. A., Rigas J. R., Grant S. C., Pisters K. M. V., Kris M. G. New chemotherapeutic agents for non-small cell lung cancer. Chest 1995; 107: 306S–311S
   Web of Science ®Google Scholar
• Cartei G., Cartei F., Cantone A., et al. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 794–800
   PubMed Web of Science ®Google Scholar
• Marino P., Pampallona S. Polychemotherapy in advanced non-small cell lung cancer. Lancet 1993; 342: 741
   PubMedGoogle Scholar
• Grilli R., Oxmam A. D., Julian J. A. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough. J Clin Oncol 1993; 11: 1866–72
   PubMed Web of Science ®Google Scholar
• Ihde D. C. Drug therapy: chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434–41
   PubMed Web of Science ®Google Scholar
• Haraf D. J., Devine S., Ihde D. C., Vokes E. E. The evolving role of systemic therapy in carcinoma of the lung. Semin Oncol 1992; 19((Suppl. 11))72–87
   PubMedGoogle Scholar
• Slevin M. L., Staquet M. J. Randomized trials in cancer. A critical review by sites. Monograph series of the European Organization for Research and Treatment of Cancer, vol. 15, Anonymous. Raven Press, New York 1986
   Google Scholar
• Buccheri G. F. Platinum-based chemotherapy for inoperable non-small cell lung cancer: a real therapeutic progress. Lung Cancer 1994; 11: 115–7
   PubMedGoogle Scholar
• Buccheri G. F., Ferrigno D., Rosso A., Vola F. Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990; 6: 87–98
   Google Scholar
• Buccheri G. F., Ferrigno D., Vola F., Curcio A. Combination of chemotherapy with methotrexate, adriamycin, cyclophosphamide, and CCNU (MACC) for non-small cell lung cancer: 4-year experience with 92 patients. Oncol 1989; 46: 212–6
   Google Scholar
• Bonomi P. D., Finkelstein D. M., Ruckdeschel J. C., et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602–13
   PubMed Web of Science ®Google Scholar
• Ellis P. A., Smith I. E., Hardy J. R., et al. Symptom relief with MVP (mitomycin C vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. BR J Cancer 1995; 2: 366–70
   Google Scholar